AllSci News
Simcere partners with Stanford Medicine on first-in-class IPF therapy with global rights option
China-based Simcere Pharmaceutical Group Limited (2096.HK) entered into a research collaboration agreement with Stanford Medicine to advance a first-in-class novel molecule for…
KAIST, Chungnam National Uni use organoid platform to identify lazertinib's utility in glioblastoma
A functional drug-screening platform built on patient-derived glioblastoma organoids predicted individual patient responses to temozolomide more accurately...
Attralus’s zamubafusp alfa wins FDA orphan designation for AL amyloidosis treatment
Naples, Florida-based Attralus, Inc. announced receipt of US FDA orphan drug designation for zamubafusp alfa (AT-02) for the treatment of immunoglobulin light…
RedHill’s SPHK2 inhibitor opaganib wins FDA rare pediatric disease designation for neuroblastoma.
RedHill Biopharma Ltd. (Nasdaq: RDHL) announced receipt of FDA rare pediatric disease (RPD) designation for opaganib (ABC294640) in neuroblastoma, adding a second…
Immunome's debuts first-in-class ADC targeting mystery immune-excluding receptor tyrosine kinase
Bothell, Washington-based Immunome, Inc. (Nasdaq: IMNM) has dosed the first patient in a Phase I first-in-human study of IM-1617, an antibody-drug conjugate...
Kardigan goes public to raise USD 373m with pipeline of cardiac myosin inhibitors
Kardigan, Inc. (Nasdaq: KARD), a Princeton, New Jersey-based clinical-stage cardiovascular therapeutics company led by the founders of MyoKardia, filed...
Chiesi completes USD 1.9b acquisition of KalVista for rare disease expansion
Italy-based Chiesi Group has completed its acquisition of Framingham, Massachusetts-based KalVista Pharmaceuticals (Nasdaq: KALV) for USD 27.00 per share in...
Takeda's zasocitinib outperforms BMS's Sotyktu in Phase III plaque psoriasis trial
Takeda (TSE:4502/NYSE:TAK) has reported that zasocitinib demonstrated statistically significant superiority over Bristol Myers Squibb's Sotyktu...
Neion Bio raises USD 23m Series A to scale egg-based bio-manufacturing
New York-based Neion Bio, Inc., a biotechnology company developing a genetic engineering-based platform for biologics manufacturing, has closed an...
Atossa raises USD 16.5m via direct offering to extend (Z)-endoxifen development runway
Seattle-based Atossa Therapeutics, Inc. (Nasdaq: ATOS) announced a registered direct offering of up to USD 16.5 million in total potential gross proceeds,...
Kuva Labs begins tender offer to buy out Lisata for RGD peptide cancer drug
Houston-based Kuva Labs Inc. has commenced a tender offer to acquire all outstanding shares of Liberty Corner, New Jersey-based Lisata Therapeutics, Inc....
BridgeBio partners with DKSH to distribute acoramidis across four Asia Pacific markets
BridgeBio's acoramidis finds a distribution partner for four Asia Pacific markets, as the oral TTR stabilizer pursues regulatory approvals in geographies...
Teva closes purchase of Emalex in USD 900m deal for neuroscience pipeline
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has closed its acquisition of Emalex Biosciences for USD 700 million upfront, with up to USD 200...
Novartis's Avidity-acquired AOC del-brax meets primary endpoint in Phase I/II FSHD trial
Novartis (SWX: NOVN.SW) reported that delpacibart braxlosiran (del-brax), its investigational antibody oligonucleotide conjugate (AOC) for...
Cordex Biologics grants Medexus Pharmaceuticals exclusive Canadian rights for Zemcelpro cell therapy
Riding its European approval, ExCellThera's Montreal-based subsidiary Cordex Biologics has signed exclusive licensing and supply agreements granting Medexus...
The AllSci Brief
Free, systematic R&D and deal news. Daily.